Rothschild & CO Asset Management Us Inc. Iovance Biotherapeutics, Inc. Transaction History
Rothschild & CO Asset Management Us Inc.
- $6.56 Billion
- Q4 2022
A detailed history of Rothschild & CO Asset Management Us Inc. transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Rothschild & CO Asset Management Us Inc. holds 418,929 shares of IOVA stock, worth $3.27 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
418,929
Previous 450,877
7.09%
Holding current value
$3.27 Million
Previous $4.32 Million
38.04%
% of portfolio
0.04%
Previous 0.07%
Shares
13 transactions
Others Institutions Holding IOVA
# of Institutions
314Shares Held
241MCall Options Held
3.77MPut Options Held
1.7M-
Vanguard Group Inc Valley Forge, PA27.3MShares$213 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY26.6MShares$208 Million6.53% of portfolio
-
Mhr Fund Management LLC New York, NY24MShares$187 Million28.52% of portfolio
-
Black Rock Inc. New York, NY21.2MShares$166 Million0.0% of portfolio
-
State Street Corp Boston, MA13.2MShares$103 Million0.01% of portfolio
About IOVANCE BIOTHERAPEUTICS, INC.
- Ticker IOVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 157,800,992
- Market Cap $1.23B
- Description
- Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...